ProCE Banner Activity

Entrectinib in ROS1-Positive NSCLC: Pooled Analysis of 3 Early-Phase Studies

Slideset Download
Conference Coverage
In this analysis, patients with ROS1+ NSCLC treated with entrectinib achieved a response rate of 77% and a median duration of response of approximately 2 years.

Released: October 02, 2018

Expiration: October 01, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants

AbbVie

AstraZeneca

Genentech TEXT Only

Takeda Oncology